MedPath
Found 1 clinical trials|View Analysis
Sort by:

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Phase 3
Recruiting
Conditions
Prostate Cancer Metastatic
Interventions
Drug: 177Lu-PMSA-617
Drug: Standard of Care
First Posted Date
2024-07-11
Last Posted Date
2024-12-20
Lead Sponsor
UNICANCER
Target Recruit Count
500
Registration Number
NCT06496581
Locations
🇫🇷

CHRU Tours, Tours, France

🇫🇷

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France

🇫🇷

Institut de Cancérologie de l'Ouest, Saint-Herblain, France

and more 20 locations
© Copyright 2025. All Rights Reserved by MedPath